Answers are grounded in this paper and cite their sources.
Background: Systemic inflammation is crucial in cancer cachexia, but the optimal measurement method remainsunclear. This study compares markers of systemic inflammation (MoSI) in predicting weight loss in patients withmetastatic cancer.Methods: This prospective, observational multi-center study involved patients undergoing radiotherapy forbone metastases. Baseline assessments included demographics, clinical characteristics, previous weight loss,and appetite loss. MoSI included: C-reactive protein (CRP), albumin, white blood cells, neutrophil-to-lymphocyteratio, monocyte-to-lymphocyte ratio, interleukin-6 (IL-6), modified Glasgow Prognostic Score (mGPS), andPrognostic Nutritional Index. Body weight was recorded at baseline, 3, and 8 weeks post-radiotherapy. Multiplelinear regression assessed MoSI’s predictive ability for weight loss, adjusting for previous weight loss, appetiteloss, and primary tumour type. Goodness-of-fit was assessed using adjusted R2.Results: Out of 574 recruited patients, 540 and 470 were analyzed at 3 and 8 weeks, respectively. The median age(IQR) was 67 (15), 330 (61%) were male, and 397 (74%) had a Karnofsky performance status ≥70. In a base modelwithout MoSI, significant predictors of weight loss at 3 weeks were appetite loss and urological, lung, and gastrointestinalcancer (adjusted R2 of 0.064), while at 8 weeks, urological and lung cancer were significant (adjusted R2of 0.035). At 3 weeks, all MoSI significantly improved the base model, with adjusted R2 between 0.078 and 0.091.At 8 weeks: CRP, mGPS, albumin and IL-6 improved the model; however only CRP and mGPS retained an adjustedR2 of ~0.09.Conclusions: All MoSI predicted weight loss, but CRP and mGPS were the most optimal.
No takes yet. Share an insight, caveat, or question.
Vagnildhaug et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: